Close Menu

More articles about Drug Discovery & Development

The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.

Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.

Studies presented at the AACR meeting demonstrated how the registry can be used to evaluate how cancer patients with rare tumor markers respond to treatments.

The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.

In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.

Although analyses for other drugs in the class have failed to confirm the influence of genotype, Dalcor is moving forward with its clinical trial, expecting some results by the end of this year.

Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.

Based on the findings, MD Anderson is already using HER2 status to recommend patients for clinical trials instead of EGFR drugs and authors recommend others follow suit.

Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.

The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.

The deal expands Lonza's portfolio of hematopoietic cell lines, including mobilized peripheral blood progenitor cells, for research applications.

Twist continues to invest in NGS while growing its core synthetic biology business, and has filed a countercomplaint in its ongoing litigation with Agilent.

The company is working with partners to identify new biomarkers and treatments as well as to collect utility evidence for its current coaching model.

With metagenomics, genomics, and other analyses, researchers saw a potential antifungal compound called cyphomycin produced by Streptomyces in an ant in Brazil.

The company intends to use the funding to expand its operations and support sales of its Cyto-Mine single-cell analysis system.

Sphere Fluidics' Cyto-Mine system automates single-cell analysis, sorting, imaging, and dispensing to help speed biopharmaceutical discovery.

Adaptive will use its T-cell receptor screening platform to identify TCRs that can be used to target individual cancer patients' neoantigens.

Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.

HitGen will apply its DNA-encoded library design, synthesis, and screening platform to discover novel leads for Bayer research endeavors.

The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.